Physician profile
Muhammad Naeem
NPI 1568431179
$18,324.60
in general payments reported to CMS, 2019-2025
62 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,196 · 2020: $1,438 · 2021: $2,489 · 2022: $2,717 · 2023: $3,183 · 2024: $3,528 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,226 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,226.49 |
| Education | $258.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,767.90 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $2,396.83 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,959.99 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Astrazeneca Pharmaceuticals LP | $1,530.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $600.64 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $594.06 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $554.70 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $506.44 | 2019-2022 | |
| Astellas Pharma US INC | $488.90 | 2019-2025 | Veozah, Myrbetriq |
| Genzyme Corporation | $456.42 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $454.82 | 2019-2025 | |
| Pfizer INC. | $425.51 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $346.59 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.92 | 2019-2023 | Synjardy, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $282.67 | 2020-2023 | Dificid |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.